Skip to main content

Table 6 Additional sensitivity analysis comparing use of 1 or 2 placebo periods for the primary analysis

From: The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

Placebo-corrected adjusted means and 90% CIs for the mean QTcN change from baseline 1−4 hours after dosing analysed using two different ANCOVA models
ANCOVA model 25 mg empagliflozin Difference from placebo, ms 200 mg empagliflozin Difference from placebo, ms
  Mean (SE) 90% CI Mean (SE) 90% CI
Primary analysis model with placebo period 1 only 0.2 (0.9) (-1.4, 1.8) -0.5 (0.8) (-1.8, 0.8)
Primary analysis model with placebo period 2 only 0.6 (1.0) (-1.2, 2.4) 0.1 (0.8) (-1.4, 1.5)
  1. Data from full analysis set (n=30). ANCOVA, analysis of covariance; CI, confidence interval; QTcN, population heart rate-corrected QT interval.